We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Notice for sparsentan (Seqirus Pty Ltd)
Active ingredients
sparsentan
Sponsor
Date of review outcome
Lapse date
Type
Orphan Drug
Dosage form(s)
film-coated tablet
Indication
For the treatment of primary immunoglobulin A nephropathy (IgAN) in adults with a urine protein excretion ≥ 1.0 g/day
Therapeutic area
Immunology